An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Trial Status: active
The purpose of this Phase 1, first in human open-label study is to assess the safety and
tolerability of TRX-103 in patients with hematological malignancies undergoing
HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is
anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment
period. TRX-103 will be infused one time post HSCT.
Inclusion Criteria
Subjects with one of the following hematologic malignancies: Acute Lymphoblastic Leukemia (B- or T-ALL), Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), or Chronic myelomonocytic leukemia (CMML)
Males and Females Age ≥ 18 years.
Weight of ≥ 35 Kg.
Karnofsky performance status ≥ 70 %.
Available mismatched related (haploidentical) or unrelated donors for peripheral blood stem cell (PBSC) donation.
Subjects must otherwise fulfill institutional criteria for eligibility to undergo allogeneic stem cell transplantation.
Absence of uncontrolled bacterial, viral or fungal infection at time of enrollment.
Have adequate organ function.
Subjects > 65-year-old receiving MAC conditioning will only be eligible if they have a HSCT-comorbidity index score < 5.
Subjects must be able to understand and sign informed consent and be willing and able to complete all specified procedures and visits.
Exclusion Criteria
Prior allogeneic bone marrow, peripheral blood, or cord blood HSCT.
Any subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support cardiac dysfunction.
HIV positive.
Positive hepatitis-B surface antigen. Subject may be included if they are HBV PCR negative.
Positive hepatitis-C antibody with positive Recombinant Immunoblot Assay (RIBA) or PCR unless the subject has received curative anti-viral treatment and confirmed negative viral load by PCR.
Received another investigational agent for treatment of disease understudy within 28 days (or 5 half-lives, whichever is shorter) of conditioning and/or have not recovered from treatment related toxicities.
Subjects with a previous history of Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS) who are not good candidates for treatment with sirolimus.
Subjects that are pregnant, breast feeding or aim to become pregnant during the study period. (Subjects must agree to use a highly effective method of contraception).
Any serious illness, uncontrolled inter-current illness, psychiatric illness, active or uncontrolled infection, or other medical condition or history, including laboratory results.
Additional locations may be listed on ClinicalTrials.gov for NCT06462365.
Locations matching your search criteria
United States
California
Duarte
City of Hope Comprehensive Cancer Center
Status: Active
Name Not Available
Massachusetts
Boston
Dana-Farber Cancer Institute
Status: Active
Name Not Available
Brigham and Women's Hospital
Status: Active
Name Not Available
Minnesota
Minneapolis
University of Minnesota/Masonic Cancer Center
Status: Active
Name Not Available
New York
New York
Memorial Sloan Kettering Cancer Center
Status: Active
Name Not Available
Washington
Seattle
Fred Hutch/University of Washington/Seattle Children's Cancer Consortium